{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["MAZ-51", "chemotherapeutics", "melanoma", "phytochemicals", "sustainable development goals", "zingerone"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38348768", "DateCompleted": {"Year": "2024", "Month": "02", "Day": "14"}, "DateRevised": {"Year": "2024", "Month": "03", "Day": "21"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1002/cbf.3950"], "ArticleDate": [], "Journal": {"ISSN": "1099-0844", "JournalIssue": {"Volume": "42", "Issue": "2", "PubDate": {"Year": "2024", "Month": "Mar"}}, "Title": "Cell biochemistry and function", "ISOAbbreviation": "Cell Biochem Funct"}, "ArticleTitle": "Decoding the synergistic potential of MAZ-51 and zingerone as therapy for melanoma treatment in alignment with sustainable development goals.", "Pagination": {"StartPage": "e3950", "MedlinePgn": "e3950"}, "Abstract": {"AbstractText": ["Melanoma, an invasive class of skin cancer, originates from mutations in melanocytes, the pigment-producing cells. Globally, approximately 132,000 new cases are reported each year, and in South Africa, the incidence stands at 2.7 per 100,000 people, signifying a worrisome surge in melanoma rates. Therefore, there is a need to explore treatment modalities that will target melanoma's signalling pathways. Melanoma metastasis is aided by ligand activity of transforming growth factor-beta 1 (TGF-\u03b21), vascular endothelial growth factor-C (VEGF-C)\u00a0and C-X-C chemokine ligand 12 (CXCL12) which bind to their receptors and promote tumour cell survival, lymphangiogenesis\u00a0and chemotaxis. (3-(4-dimethylaminonaphthelen-1-ylmethylene)-1,3-dihydroindol-2-one) MAZ-51 is an indolinone-based molecule that inhibits VEGF-C induced phosphorylation of vascular endothelial growth factor receptor 3 (VEGFR-3). Despite the successful use of conventional cancer therapies, patients endure adverse side effects and cancer drug resistance. Moreover, conventional therapies are toxic to the environment and caregivers. The use of medicinal plants and their phytochemical constituents in cancer treatment strategies has become more widespread because of the rise in drug resistance and the development of unfavourable side effects. Zingerone, a phytochemical derived from ginger exhibits various pharmacological properties positioning it as a promising candidate for cancer treatment. This review provides an overview of melanoma biology and the intracellular signalling pathways promoting cell survival, proliferation\u00a0and adhesion. There is a need to align health and environmental objectives within sustainable development goals 3 (good health and well-being), 13 (climate action)\u00a0and 15 (life on land) to promote early detection of skin cancer, enhance sun-safe practices, mitigation of environmental factors\u00a0and advancing the preservation of biodiversity, including medicinal plants. Thus, this review discusses the impact of cytostatic cancer drugs on patients and the environment and examines the potential use of phytochemicals as adjuvant therapy."], "CopyrightInformation": "\u00a9 2024 The Authors. Cell Biochemistry and Function published by John Wiley & Sons Ltd."}, "AuthorList": [{"Identifier": ["0000-0003-1679-5293"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Physiology, University of Pretoria, Pretoria, South Africa."}], "LastName": "Letsoalo", "ForeName": "Kganya", "Initials": "K"}, {"Identifier": ["0000-0002-0042-4466"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Physiology, University of Pretoria, Pretoria, South Africa."}], "LastName": "Nortje", "ForeName": "Evangeline", "Initials": "E"}, {"Identifier": ["0000-0002-0364-0068"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Environmental Chemical Pollution and Health Research Unit, University of Pretoria, Pretoria, South Africa."}], "LastName": "Patrick", "ForeName": "Sean", "Initials": "S"}, {"Identifier": ["0000-0003-1872-9257"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Physiology, University of Pretoria, Pretoria, South Africa."}], "LastName": "Nyakudya", "ForeName": "Trevor", "Initials": "T"}, {"Identifier": ["0000-0002-3112-2436"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Physiology, University of Pretoria, Pretoria, South Africa."}], "LastName": "Hlophe", "ForeName": "Yvette", "Initials": "Y"}], "GrantList": [{"GrantID": "N1F580A1F685", "Agency": "National Research Foundation", "Country": ""}, {"Agency": "University of Pretoria Postgraduate Funding Scheme", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Cell Biochem Funct", "NlmUniqueID": "8305874", "ISSNLinking": "0263-6484"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Vascular Endothelial Growth Factor C"}, {"RegistryNumber": "4MMW850892", "NameOfSubstance": "zingerone"}, {"RegistryNumber": "0", "NameOfSubstance": "Vascular Endothelial Growth Factor A"}, {"RegistryNumber": "0", "NameOfSubstance": "Ligands"}, {"RegistryNumber": "0", "NameOfSubstance": "Phytochemicals"}, {"RegistryNumber": "6JKA7MAH9C", "NameOfSubstance": "Guaiacol"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism"], "DescriptorName": "Melanoma"}, {"QualifierName": ["metabolism"], "DescriptorName": "Vascular Endothelial Growth Factor C"}, {"QualifierName": [], "DescriptorName": "Vascular Endothelial Growth Factor A"}, {"QualifierName": [], "DescriptorName": "Ligands"}, {"QualifierName": [], "DescriptorName": "Sustainable Development"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Skin Neoplasms"}, {"QualifierName": [], "DescriptorName": "Phytochemicals"}, {"QualifierName": ["analogs & derivatives"], "DescriptorName": "Guaiacol"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Garcia\u2010Oliveira P, Otero P, Pereira AG, et al. Status and challenges of plant\u2010anticancer compounds in cancer treatment. Pharmaceuticals. 2021;14(2):157. doi:10.3390/ph14020157"}, {"Citation": "The World Health Organization. Cancer. The World Health Organization. https://www.who.int/health-topics/cancer#tab=tab_1"}, {"Citation": "Gordon R. Skin cancer: an overview of epidemiology and risk factors. Semin Oncol Nurs. 2013;29(3):160\u2010169. doi:10.1016/j.soncn.2013.06.002"}, {"Citation": "Arnold M, Singh D, Laversanne M, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158(5):495\u2010503. doi:10.1001/jamadermatol.2022.0160"}, {"Citation": "Nkandeu DS, Basson C, Joubert AM, et al. The involvement of a chemokine receptor antagonist CTCE\u20109908 and kynurenine metabolites in cancer development. Cell Biochem Funct. 2022;40:608\u2010622. doi:10.1002/cbf.3731"}, {"Citation": "Eddy K, Chen S. Overcoming immune evasion in melanoma. Int J Mol Sci. 2020;21(23):8984. doi:10.3390/ijms21238984"}, {"Citation": "Juszczak AM, W\u00f6elfle U, Kon\u010di\u0107 MZ, Tomczyk M. Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeutics. Med Res Rev. 2022;42(4):1423\u20101462. doi:10.1002/med.21880"}, {"Citation": "Dika E, Patrizi A, Lambertini M, et al. Estrogen receptors and melanoma: a review. Cells. 2019;8(11):1463. doi:10.3390/cells8111463"}, {"Citation": "Morgese F, Sampaolesi C, Torniai M, et al. Gender differences and outcomes in melanoma patients. Onco Ther. 2020;8(1):103\u2010114. doi:10.1007/s40487-020-00109-1"}, {"Citation": "Roh MR, Eliades P, Gupta S, Grant\u2010Kels JM, Tsao H. Cutaneous melanoma in women. Int J Womens Dermatol. 2015;1:21\u201025. doi:10.1016/j.ijwd.2015.01.001"}, {"Citation": "Balwierz R, Biernat P, Jasi\u0144ska\u2010Balwierz A, et al. Potential carcinogens in makeup cosmetics. Int J Environ Res Public Health. 2023;20(6):4780. doi:10.3390/ijerph20064780"}, {"Citation": "Budden T, Bowden N. The role of altered nucleotide excision repair and UVB\u2010induced DNA damage in melanomagenesis. Int J Mol Sci. 2013;14(1):1132\u20101151. doi:10.3390/ijms14011132"}, {"Citation": "Rass K, Reichrath J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008;624:162\u2010178. doi:10.1007/978-0-387-77574-6_13"}, {"Citation": "Leonardi G, Falzone L, Salemi R, et al. Cutaneous melanoma: from pathogenesis to therapy (Review. Int J Oncol. 2018;52(4):1071\u20101080. doi:10.3892/ijo.2018.4287"}, {"Citation": "Strashilov S, Yordanov A. Aetiology and pathogenesis of cutaneous melanoma: current concepts and advances. Int J Mol Sci. 2021;22(12):6395. doi:10.3390/ijms22126395"}, {"Citation": "Burns D, George J, Aucoin D, et al. The pathogenesis and clinical management of cutaneous melanoma: an evidence\u2010based review. J Med Imaging Radiat Sci. 2019;50(3):460\u2010469. doi:10.1016/j.jmir.2019.05.001"}, {"Citation": "Paluncic J, Kovacevic Z, Jansson PJ, et al. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta\u2010Mol Cell Res. 2016;1863(4):770\u2010784. doi:10.1016/j.bbamcr.2016.01.025"}, {"Citation": "Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence\u2010based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u2010492. doi:10.3322/caac.21409."}, {"Citation": "Bunnell AM, Nedrud SM, Fernandes RP. Classification and staging of melanoma in the head and neck. Oral Maxillofac Surg Clin North Am. 2022;34(2):221\u2010234. doi:10.1016/j.coms.2021.12.001"}, {"Citation": "Ward WH, Lambreton F, Goel N, Yu JQ, Farma JM. Clinical presentation and staging of melanoma. In: Ward WH, Farma JM, eds. Cutaneous Melanoma: Etiology and Therapy. Codon Publications; 2017."}, {"Citation": "Chandra Pal H, Marchiony Hunt K, Diamond A, A. Elmets C, Afaq F. Phytochemicals for the management of melanoma. Mini Rev Med Chem. 2016;16(12):953\u2010979. doi:10.2174/1389557516666160211120157"}, {"Citation": "El Sharouni MA, van Diest PJ, Witkamp AJ, Sigurdsson V, van Gils CH. Subtyping cutaneous melanoma matters. JNCI Cancer Spectr. 2020;4(6):pkaa097. doi:10.1093/jncics/pkaa097"}, {"Citation": "Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366\u20101379. doi:10.1080/15384047.2019.1640032"}, {"Citation": "Luke JJ, Schwartz GK. Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol. 2013;31(3):290\u2010297. doi:10.1016/j.clindermatol.2012.08.016"}, {"Citation": "Jiang G, Li RH, Sun C, Liu YQ, Zheng JN. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta\u2010analysis. PLoS One. 2014;9(12):e111920. doi:10.1371/journal.pone.0111920"}, {"Citation": "Pham JP, Joshua AM, da Silva IP, Dummer R, Goldinger SM. Chemotherapy in cutaneous melanoma: is there still a role? Curr Oncol Rep. 2023;25(6):609\u2010621. doi:10.1007/s11912-023-01385-6"}, {"Citation": "Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22(11):2101\u20102107. doi:10.1200/jco.2004.11.044"}, {"Citation": "Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002;12(2):175\u2010178. doi:10.1097/00008390-200204000-00011"}, {"Citation": "Khattak M, Fisher R, Turajlic S, Larkin J. Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol. 2013;5(2):105\u2010118. doi:10.1177/1758834012466280"}, {"Citation": "Milija\u0161evi\u0107 B, Stefanovi\u0107 D, Lali\u0107\u2010Popovi\u0107 M, et al. Acute toxic effects of single dose dacarbazine: hematological and histological changes in an animal model. Biotech Histochem. 2014;89(8):583\u2010590. doi:10.3109/10520295.2014.918653"}, {"Citation": "Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int. 2015;2015:413076. doi:10.1155/2015/413076"}, {"Citation": "Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u2010378. doi:10.1016/j.ejphar.2014.07.025"}, {"Citation": "Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013;31(14):1767\u20101774. doi:10.1200/jco.2012.44.7888"}, {"Citation": "Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (Temodar. AJNR Am J Neuroradiol. 2010;31(8):1383\u20101384. doi:10.3174/ajnr.A2170"}, {"Citation": "Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune\u2010related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep. 2020;22(4):39. doi:10.1007/s11912-020-0897-9"}, {"Citation": "Youssef G, Dietrich J. Ipilimumab: an investigational immunotherapy for glioblastoma. Expert Opin Investig Drugs. 2020;29(11):1187\u20101193. doi:10.1080/13543784.2020.1826436"}, {"Citation": "Koppolu V, Rekha Vasigala VK. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. J Cancer Res Ther. 2018;14(6):1167\u20101175. doi:10.4103/jcrt.JCRT_1290_16"}, {"Citation": "Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201060. doi:10.1016/j.ctrv.2016.02.001"}, {"Citation": "Sak K. Chemotherapy and dietary phytochemical agents. Chemother Res Pract. 2012;2012:1\u201011. doi:10.1155/2012/282570"}, {"Citation": "Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233. doi:10.3390/ijms21093233"}, {"Citation": "Kodama S, Podyma\u2011inoue K, Uchihashi T, et al. Progression of melanoma is suppressed by targeting all transforming growth factor\u2011\u03b2 isoforms with an Fc chimeric receptor. Oncol Rep. 2021;46(3):197. doi:10.3892/or.2021.8148"}, {"Citation": "Yuan Y, Jiang YC, Sun CK, Chen QM. Role of the tumor microenvironment in tumor progression and the clinical applications (review). Oncol Rep. 2016;35(5):2499\u20102515. doi:10.3892/or.2016.4660"}, {"Citation": "Elias EG, Hasskamp JH, Sharma BK. Cytokines and growth factors expressed by human cutaneous melanoma. Cancers. 2010;2(2):794\u2010808. doi:10.3390/cancers2020794"}, {"Citation": "Wang X, Montoyo\u2010Pujol YG, Bermudez S, et al. Serum cytokine profiles of melanoma patients and their association with tumor progression and metastasis. J Oncol. 2021;2021:1\u20109. doi:10.1155/2021/6610769"}, {"Citation": "Hoejberg L, Bastholt L, Schmidt H. Interleukin\u20106 and melanoma. Melanoma Res. 2012;22(5):327\u2010333. doi:10.1097/CMR.0b013e3283543d72"}, {"Citation": "Chen W, Ten Dijke P. Immunoregulation by members of the TGF\u03b2 superfamily. Nat Rev Immunol. 2016;16(12):723\u2010740. doi:10.1038/nri.2016.112"}, {"Citation": "Syed V. TGF\u2010\u03b2 signaling in cancer. J Cell Biochem. 2016;117(6):1279\u20101287. doi:10.1002/jcb.25496"}, {"Citation": "Liu S, Chen S, Zeng J. TGF\u2011\u03b2 signaling: a complex role in tumorigenesis (Review). Mol Med Rep. 2017;17(1):699\u2010704. doi:10.3892/mmr.2017.7970"}, {"Citation": "Papageorgis P, Stylianopoulos T. Role of TGF\u03b2 in regulation of the tumor microenvironment and drug delivery (review). Int J Oncol. 2015;46(3):933\u2010943. doi:10.3892/ijo.2015.2816"}, {"Citation": "Seoane J, Gomis RR. TGF\u2010\u03b2 family signaling in tumor suppression and cancer progression. Cold Spring Harbor Perspect Biol. 2017;9(12):a022277. doi:10.1101/cshperspect.a022277"}, {"Citation": "Margadant C, Sonnenberg A. Integrin\u2013TGF\u2010\u03b2 crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010;11(2):97\u2010105. doi:10.1038/embor.2009.276"}, {"Citation": "Javelaud D, Alexaki VI, Mauviel A. Transforming growth factor\u2010\u03b2 in cutaneous melanoma. Pigm Cell Melanoma Res. 2008;21(2):123\u2010132. doi:10.1111/j.1755-148X.2008.00450.x"}, {"Citation": "Pak KH, Park KC, Cheong JH. VEGF\u2010C induced by TGF\u2010 \u03b21 signaling in gastric cancer enhances tumor\u2010induced lymphangiogenesis. BMC Cancer. 2019;19(1):799. doi:10.1186/s12885-019-5972-y"}, {"Citation": "Viallard C, Larriv\u00e9e B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20(4):409\u2010426. doi:10.1007/s10456-017-9562-9"}, {"Citation": "Ye X, Gaucher JF, Vidal M, Broussy S. A structural overview of vascular endothelial growth factors pharmacological ligands: from macromolecules to designed peptidomimetics. Molecules. 2021;26(22):6759. doi:10.3390/molecules26226759"}, {"Citation": "Chen JC, Chang YW, Hong CC, Yu YH, Su JL. The role of the VEGF\u2010C/VEGFRs axis in tumor progression and therapy. Int J Mol Sci. 2012;14(1):88\u2010107. doi:10.3390/ijms14010088"}, {"Citation": "Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248\u20101264. doi:10.1016/j.cell.2019.01.021"}, {"Citation": "Koch S, Claesson\u2010Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harbor Perspect Med. 2012;2(7):a006502. doi:10.1101/cshperspect.a006502"}, {"Citation": "Pastushenko I, Conejero C, Carapeto FJ. La linfangiog\u00e9nesis. Sus implicaciones en el diagn\u00f3stico, tratamiento y pron\u00f3stico del melanoma. Actas Dermosifiliogr. 2015;106(1):7\u201016. doi:10.1016/j.ad.2014.02.013"}, {"Citation": "Wang M, Xu Y, Wen GZ, Wang Q, Yuan SM. Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF\u2010A/VEGFR\u20102 and VEGF\u2010C/VEGFR\u20103 expression. Onco Targets Ther. 2019;12:4643\u20104654. doi:10.2147/ott.S205160"}, {"Citation": "Wissmann C, Detmar M. Pathways targeting tumor lymphangiogenesis. Clin Cancer Res. 2006;12(23):6865\u20106868. doi:10.1158/1078-0432.Ccr-06-1800"}, {"Citation": "Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene. 2003;22(20):3172\u20103179. doi:10.1038/sj.onc.1206457"}, {"Citation": "Raica M, Jitariu AA, Cimpean AM. Lymphangiogenesis and anti\u2010lymphangiogenesis in cutaneous melanoma. Anticancer Res. 2016;36(9):4427\u20104436. doi:10.21873/anticanres.10986"}, {"Citation": "Liu B, Ma J, Wang X, et al. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma. Anat Rec. 2008;291(10):1227\u20101235. doi:10.1002/ar.20736"}, {"Citation": "Cianfarani F, Mastroeni S, Odorisio T, et al. Expression of vascular endothelial growth factor\u2010C in primary cutaneous melanoma predicts sentinel lymph node positivity. J Cutan Pathol. 2012;39(9):826\u2010834. doi:10.1111/j.1600-0560.2012.01955.x"}, {"Citation": "Cheresh DA. Monographs editor. Genes Cancer. 2011;2:1071. doi:10.1177/1947601911431886"}, {"Citation": "Gillot L, Baudin L, Rouaud L, Kridelka F, No\u00ebl A. The pre\u2010metastatic niche in lymph nodes: formation and characteristics. Cell Mol Life Sci. 2021;78(16):5987\u20106002. doi:10.1007/s00018-021-03873-z"}, {"Citation": "Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31\u201082. doi:10.1016/b978-0-12-411638-2.00002-1"}, {"Citation": "Jacquelot N, Duong CPM, Belz GT, Zitvogel L. Targeting chemokines and chemokine receptors in melanoma and other cancers. Front Immunol. 2018;9:2480. doi:10.3389/fimmu.2018.02480"}, {"Citation": "Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285(16):2944\u20102971. doi:10.1111/febs.14466"}, {"Citation": "Wang Y, Xie Y, Oupick\u00fd D. Potential of CXCR4/CXCL12 chemokine axis in cancer drug delivery. Curr Pharmacol Rep. 2016;2(1):1\u201010. doi:10.1007/s40495-015-0044-8"}, {"Citation": "Mitchell B, Mahalingam M. The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma. Histol\u00a0Histopathol. 2014;29(12):1539\u20101546. doi:10.14670/hh-29.1539"}, {"Citation": "Kim J, Mori T, Chen SL, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006;244(1):113\u2010120. doi:10.1097/01.sla.0000217690.65909.9c"}, {"Citation": "Andr\u00e9 ND, Silva VAO, Ariza CB, Watanabe MAE, De Lucca FL. In vivo knockdown of CXCR4 using jetPEI/CXCR4 shRNA nanoparticles inhibits the pulmonary metastatic potential of B16\u2011F10 melanoma cells. Mol Med Rep. 2015;12(6):8320\u20108326. doi:10.3892/mmr.2015.4487"}, {"Citation": "O'Boyle G, Swidenbank I, Marshall H, et al. Inhibition of CXCR4\u2010CXCL12 chemotaxis in melanoma by AMD11070. Br J Cancer. 2013;108(8):1634\u20101640. doi:10.1038/bjc.2013.124"}, {"Citation": "Karaman S, Detmar M. Mechanisms of lymphatic metastasis. J Clin Invest. 2014;124(3):922\u2010928. doi:10.1172/jci71606"}, {"Citation": "Teicher BA, Fricker SP. CXCL12 (SDF\u20101)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927\u20102931. doi:10.1158/1078-0432.Ccr-09-2329"}, {"Citation": "Stone M, Hayward J, Huang C, E. Huma Z, Sanchez J. Mechanisms of regulation of the chemokine\u2010receptor network. Int J Mol Sci. 2017;18(2):342. doi:10.3390/ijms18020342"}, {"Citation": "Zhao R, Liu J, Li Z, Zhang W, Wang F, Zhang B. Recent advances in CXCL12/CXCR4 antagonists and nano\u2010based drug delivery systems for cancer therapy. Pharmaceutics. 2022;14(8):1541. doi:10.3390/pharmaceutics14081541"}, {"Citation": "Bianchi ME, Mezzapelle R. The chemokine receptor CXCR4 in cell proliferation and tissue regeneration. Front Immunol. 2020;11:2109. doi:10.3389/fimmu.2020.02109"}, {"Citation": "Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9\u201022. doi:10.1038/nrc2748"}, {"Citation": "Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35(3):347\u2010367. doi:10.1016/j.ccell.2019.01.007"}, {"Citation": "Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:1\u201010. doi:10.1155/2012/676731"}, {"Citation": "Mousson A, Legrand M, Steffan T, et al. Inhibiting FAK\u2010paxillin interaction reduces migration and invadopodia\u2010mediated matrix degradation in metastatic melanoma cells. Cancers. 2021;13(8):1871. doi:10.3390/cancers13081871"}, {"Citation": "Murphy JM, Rodriguez YAR, Jeong K, Ahn EYE, Lim STS. Targeting focal adhesion kinase in cancer cells and the tumor microenvironment. Exp Mol Med. 2020;52(6):877\u2010886. doi:10.1038/s12276-020-0447-4"}, {"Citation": "Golubovskaya VM, Finch R, Kweh F, et al. p53 regulates FAK expression in human tumor cells. Mol Carcinog. 2008;47(5):373\u2010382. doi:10.1002/mc.20395"}, {"Citation": "Tai YL, Chen LC, Shen TL. Emerging roles of focal adhesion kinase in cancer. BioMed Res Int. 2015;2015:1\u201013. doi:10.1155/2015/690690"}, {"Citation": "Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta Mol Cell Res. 2013;1833(12):3481\u20103498. doi:10.1016/j.bbamcr.2013.06.026"}, {"Citation": "Horowitz JC, Rogers DS, Sharma V, et al. Combinatorial activation of FAK and AKT by transforming growth factor\u2010\u03b21 confers an anoikis\u2010resistant phenotype to myofibroblasts. Cell Signal. 2007;19(4):761\u2010771. doi:10.1016/j.cellsig.2006.10.001"}, {"Citation": "Hlophe YN, Joubert AM. Vascular endothelial growth factor\u2010C in activating vascular endothelial growth factor receptor\u20103 and chemokine receptor\u20104 in melanoma adhesion. J Cell Mol Med. 2022;26(23):5743\u20105754. doi:10.1111/jcmm.17571"}, {"Citation": "L\u00f3pez\u2010Colom\u00e9 AM, Lee\u2010Rivera I, Benavides\u2010Hidalgo R, L\u00f3pez E. Paxillin: a crossroad in pathological cell migration. J Hematol Oncol. 2017;10(1):50. doi:10.1186/s13045-017-0418-y"}, {"Citation": "Liu W, Huang X, Luo W, Liu X, Chen W. The role of paxillin aberrant expression in cancer and its potential as a target for cancer therapy. Int J Mol Sci. 2023;24(9):8245. doi:10.3390/ijms24098245"}, {"Citation": "Velasco\u2010Vel\u00e1zquez MA, Salinas\u2010Jazm\u00edn N, Mendoza\u2010Pati\u00f1o N, Mandoki JJ. Reduced paxillin expression contributes to the antimetastatic effect of 4\u2010hydroxycoumarin on B16\u2010F10 melanoma cells. Cancer Cell Int. 2008;8:8. doi:10.1186/1475-2867-8-8"}, {"Citation": "Park JH, Shin YJ, Riew TR, Lee MY. The indolinone MAZ51 induces cell rounding and G2/M cell cycle arrest in glioma cells without the inhibition of VEGFR\u20103 phosphorylation: involvement of the RhoA and Akt/GSK3\u03b2 signaling pathways. PLoS One. 2014;9(9):e109055. doi:10.1371/journal.pone.0109055"}, {"Citation": "Lee JY, Hong SH, Shin M, Heo HR, Jang IH. Blockade of FLT4 suppresses metastasis of melanoma cells by impaired lymphatic vessels. Biochem Biophys Res Commun. 2016;478(2):733\u2010738. doi:10.1016/j.bbrc.2016.08.017"}, {"Citation": "\u0160piri\u0107 Z, Eri \u017d, Eri\u0107 M. Significance of vascular endothelial growth factor (VEGF)\u2010C and VEGF\u2010D in the progression of cutaneous melanoma. Int J Surg Pathol. 2015;23(8):629\u2010637. doi:10.1177/1066896915583694"}, {"Citation": "Sagbo IJ, Otang\u2010Mbeng W. Plants used for the traditional management of cancer in the eastern cape province of South Africa: a review of ethnobotanical surveys, ethnopharmacological studies and active phytochemicals. Molecules. 2021;26(15):4639. doi:10.3390/molecules26154639"}, {"Citation": "Sofowora A, Ogunbodede E, Onayade A. The role and place of medicinal plants in the strategies for disease prevention. Afr J Tradit Complement Altern Med. 2013;10(5):210\u2010229. doi:10.4314/ajtcam.v10i5.2"}, {"Citation": "Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front Pharmacol. 2020;10:1614. doi:10.3389/fphar.2019.01614"}, {"Citation": "Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harbor Perspect Med. 2015;5(4):a006098. doi:10.1101/cshperspect.a006098"}, {"Citation": "Ayaz M, Nawaz A, Ahmad S, et al. Underlying anticancer mechanisms and synergistic combinations of phytochemicals with cancer chemotherapeutics: potential benefits and risks. J Food Quality. 2022;2022:1\u201015. doi:10.1155/2022/1189034"}, {"Citation": "Pal HC, Sharma S, Strickland LR, et al. Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NF\u03baB signaling pathways. PLoS One. 2014;9(1):e86338. doi:10.1371/journal.pone.0086338"}, {"Citation": "Aronchik I, Kundu A, Quirit JG, Firestone GL. The antiproliferative response of indole\u20103\u2010carbinol in human melanoma cells is triggered by an interaction with NEDD4\u20101 and disruption of wild\u2010type PTEN degradation. Mol Cancer Res. 2014;12(11):1621\u20101634. doi:10.1158/1541-7786.Mcr-14-0018"}, {"Citation": "Ravindran Menon D, Li Y, Yamauchi T, et al. EGCG inhibits tumor growth in melanoma by targeting JAK\u2010STAT signaling and its downstream PD\u2010L1/PD\u2010L2\u2010PD1 axis in tumors and enhancing cytotoxic T\u2010cell responses. Pharmaceuticals. 2021;14(11):1081. doi:10.3390/ph14111081"}, {"Citation": "Ghosh R, Nadiminty N, Fitzpatrick JE, Alworth WL, Slaga TJ, Kumar AP. Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity. J Biol Chem. 2005;280(7):5812\u20105819. doi:10.1074/jbc.M411429200"}, {"Citation": "Pourhanifeh MH, Abbaszadeh\u2010Goudarzi K, Goodarzi M, et al. Resveratrol: a new potential therapeutic agent for melanoma? Curr Med Chem. 2021;28(4):687\u2010711. doi:10.2174/0929867326666191212101225"}, {"Citation": "Vaid M, Singh T, Prasad R, Katiyar SK. Silymarin inhibits melanoma cell growth both in vitro and in vivo by targeting cell cycle regulators, angiogenic biomarkers and induction of apoptosis. Mol Carcinog. 2015;54(11):1328\u20101339. doi:10.1002/mc.22208"}, {"Citation": "Bae J, Kumazoe M, Murata K, Fujimura Y, Tachibana H. Procyanidin C1 inhibits melanoma cell growth by activating 67\u2010kDa laminin receptor signaling. Mol Nutr Food Res. 2020;64(7):e1900986. doi:10.1002/mnfr.201900986"}, {"Citation": "Rocchetti MT, Bellanti F, Zadorozhna M, Fiocco D, Mangieri D. Multi\u2010faceted role of luteolin in cancer metastasis: EMT, angiogenesis, ECM degradation and apoptosis. Int J Mol Sci. 2023;24(10):8824. doi:10.3390/ijms24108824"}, {"Citation": "Yao X, Jiang W, Yu D, Yan Z. Luteolin inhibits proliferation and induces apoptosis of human melanoma cells in vivo and in vitro by suppressing MMP\u20102 and MMP\u20109 through the PI3K/AKT pathway. Food Funct. 2019;10(2):703\u2010712. doi:10.1039/c8fo02013b"}, {"Citation": "Russo M, Spagnuolo C, Tedesco I, Russo GL. Phytochemicals in cancer prevention and therapy: truth or dare? Toxins. 2010;2(4):517\u2010551. doi:10.3390/toxins2040517"}, {"Citation": "Rizeq B, Gupta I, Ilesanmi J, AlSafran M, Rahman MM, Ouhtit A. The power of phytochemicals combination in cancer chemoprevention. J Cancer. 2020;11(15):4521\u20104533. doi:10.7150/jca.34374"}, {"Citation": "Rodriguez S, Skeet K, Mehmetoglu\u2010Gurbuz T, et al. Phytochemicals as an alternative or integrative option, in conjunction with conventional treatments for hepatocellular carcinoma. Cancers. 2021;13(22):5753. doi:10.3390/cancers13225753"}, {"Citation": "Ahmad B, Rehman MU, Amin I, et al. A review on pharmacological properties of zingerone (4\u2010(4\u2010hydroxy\u20103\u2010methoxyphenyl)\u20102\u2010butanone). Sci World J. 2015;2015:1\u20106. doi:10.1155/2015/816364"}, {"Citation": "Amer R. The possible protective role of zingerone on ethanol induced entrotoxicity of jejunum in adult albino rats: light and scanning electron microscopic study. J Microsc Ultrastruct. 2020;8(2):69\u201074. doi:10.4103/jmau.Jmau_55_19"}, {"Citation": "Choi JS, Ryu J, Bae WY, et al. Zingerone suppresses tumor development through decreasing cyclin D1 expression and inducing mitotic arrest. Int J Mol Sci. 2018;19(9):2832. doi:10.3390/ijms19092832"}, {"Citation": "Qian S, Fang H, Zheng L, Liu M. Zingerone suppresses cell proliferation via inducing cellular apoptosis and inhibition of the PI3K/AKT/mTOR signaling pathway in human prostate cancer PC\u20103 cells. J Biochem Mol Toxicol. 2021;35(1):e22611. doi:10.1002/jbt.22611"}, {"Citation": "Lee J, Oh SW, Shin SW, Lee KW, Cho JY, Lee J. Zingerone protects keratinocyte stem cells from UVB\u2010induced damage. Chem\u2010Biol Interact. 2018;279:27\u201033. doi:10.1016/j.cbi.2017.11.004"}, {"Citation": "Chaudhuri RK, Meyer T, Premi S, Brash D. Acetyl zingerone: an efficacious multifunctional ingredient for continued protection against ongoing DNA damage in melanocytes after sun exposure ends. Int J Cosmet Sci. 2020;42(1):36\u201045. doi:10.1111/ics.12582"}, {"Citation": "Meyer TA, Swindell WR, Chaudhuri RK. Acetyl zingerone: a photostable multifunctional skincare ingredient that combats features of intrinsic and extrinsic skin aging. Antioxidants. 2023;12(6):1168. doi:10.3390/antiox12061168"}, {"Citation": "Srivastava J, Young MM, Yadav VK, et al. The role of acetyl zingerone and its derivatives in inhibiting UV\u2010induced, incident, and delayed cyclobutane pyrimidine dimers. Antioxidants. 2023;12(2):278. doi:10.3390/antiox12020278"}, {"Citation": "Bhaskar Chandra Sahoo SS, Nayak S, Kar B. Pharmacological activity and biochemical interaction of Zingerone: a flavour additive in spice food. Plant Sci Today. 2022;9(1):81\u201088."}, {"Citation": "Su P, Veeraraghavan VP, Krishna Mohan S, Lu W. A ginger derivative, zingerone\u2010a phenolic compound\u2010induces ROS\u2010mediated apoptosis in colon cancer cells (HCT\u2010116). J Biochem Mol Toxicol. 2019;33(12):e22403. doi:10.1002/jbt.22403"}, {"Citation": "Sagwal SK, Bekeschus S. ROS pleiotropy in melanoma and local therapy with physical modalities. Oxid Med Cell Longevity. 2021;2021:1\u201021. doi:10.1155/2021/6816214"}, {"Citation": "Wormington AM, De Mar\u00eda M, Kurita HG, Bisesi JH\u00a0Jr., Denslow ND, Martyniuk CJ. Antineoplastic agents: environmental prevalence and adverse outcomes in aquatic organisms. Environ Toxicol Chem. 2020;39(5):967\u2010985. doi:10.1002/etc.4687"}, {"Citation": "Li D, Chen H, Liu H, et al. Anticancer drugs in the aquatic ecosystem: environmental occurrence, ecotoxicological effect and risk assessment. Environ Int. 2021;153:106543. doi:10.1016/j.envint.2021.106543"}, {"Citation": "Ribeiro F, Costa\u2010Lotufo L, Loureiro S, Pavlaki MD. Environmental hazard of anticancer drugs: state of the art and future perspective for marine organisms. Environ Toxicol Chem. 2022;41(8):1793\u20101807. doi:10.1002/etc.5397"}, {"Citation": "Yadav A, Rene ER, Mandal MK, Dubey KK. Threat and sustainable technological solution for antineoplastic drugs pollution: review on a persisting global issue. Chemosphere. 2021;263:128285. doi:10.1016/j.chemosphere.2020.128285"}, {"Citation": "Heath E, Filipi\u010d M, Kosjek T, Isidori M. Fate and effects of the residues of anticancer drugs in the environment. Environ Sci Pollut Res. 2016;23(15):14687\u201014691. doi:10.1007/s11356-016-7069-3"}, {"Citation": "Li D, Sun W, Chen H, et al. Cyclophosphamide affects eye development and locomotion in zebrafish (Danio rerio). Sci Total Environ. 2022;805:150460. doi:10.1016/j.scitotenv.2021.150460"}, {"Citation": "Novak M, \u017degura B, Modic B, Heath E, Filipi\u010d M. Cytotoxicity and genotoxicity of anticancer drug residues and their mixtures in experimental model with zebrafish liver cells. Sci Total Environ. 2017;601\u2010602:293\u2010300. doi:10.1016/j.scitotenv.2017.05.115"}, {"Citation": "Jureczko M, Kalka J. Cytostatic pharmaceuticals as water contaminants. Eur J Pharmacol. 2020;866:172816. doi:10.1016/j.ejphar.2019.172816"}, {"Citation": "Viegas S, Ladeira C, Costa\u2010Veiga A, Perelman J, Gajski G. Forgotten public health impacts of cancer\u2014an overview. Arch Ind Hyg Toxicol. 2017;68(4):287\u2010297. doi:10.1515/aiht-2017-68-3005"}, {"Citation": "Baniasadi S, Alehashem M, Yunesian M, Rastkari N. Biological monitoring of healthcare workers exposed to antineoplastic drugs: urinary assessment of cyclophosphamide and ifosfamide. Iran J Pharm Res. 2018;17(4):1458\u20101464."}, {"Citation": "Elshaer N. Adverse health effects among nurses and clinical pharmacists handling antineoplastic drugs: adherence to exposure control methods. J Egypt Public Health Assoc. 2017;92(3):144\u2010155."}, {"Citation": "The World Bank. Blue Economy. The World Bank; 2022. https://www.worldbank.org/en/topic/oceans-fisheries-and-coastal-economies"}, {"Citation": "SADC\u2010EU EPA. South African Fisheries and the SACD\u2010EU Economic Partnership Agreement. SADC\u2010EU EPA; 2017. https://sadc-epa-outreach.com/images/files/sadc-eu-epa-fisheries-july-2017.pdf"}, {"Citation": "Dhupal M, Chowdhury D. Phytochemical\u2010based nanomedicine for advanced cancer theranostics: perspectives on clinical trials to clinical use. Int J Nanomedicine. 2020;15:9125\u20109157. doi:10.2147/ijn.S259628"}, {"Citation": "Fasinu PS, Rapp GK. Herbal interaction with chemotherapeutic drugs\u2014a focus on clinically significant findings. Front Oncol. 2019;9:1356. doi:10.3389/fonc.2019.01356"}, {"Citation": "Yeung KS, Gubili J, Mao JJ. Herb\u2010drug interactions in cancer care. Oncology. 2018;32(10):516\u2010520."}], "Title": "REFERENCES"}], "History": [{"Year": "2023", "Month": "12", "Day": "28"}, {"Year": "2023", "Month": "9", "Day": "25"}, {"Year": "2024", "Month": "1", "Day": "29"}, {"Year": "2024", "Month": "2", "Day": "14", "Hour": "12", "Minute": "42"}, {"Year": "2024", "Month": "2", "Day": "13", "Hour": "6", "Minute": "46"}, {"Year": "2024", "Month": "2", "Day": "13", "Hour": "5", "Minute": "38"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38348768", "10.1002/cbf.3950"]}}]}